Resistance to azole antifungal agents in Candida albicans can be mediated by multidrug efflux transporters. In a previous study, w e identified a t least two such transporters, C d r l p and Benp, which belong to the class of ATP-binding -cassette (ABC) transporters and of major facilitators, respectively. To isolate additional factors potentially responsible for resistance to azole antifungal agents in C. albicans, the hypersusceptibility of a Saccharomyces cerevisiae multidrug transporter mutant, Apdr5, to these agents was complemented with a C. albicans genomic library. Several new genes were isolated, one of which was a new ABC transporter gene called CDR2 (Candida drug Eesistance). The protein Cdr2p encoded b y this gene exhibited 84% identity with C d r l p and could confer resistance to azole antif ungal agents, to other antifungals (terbinafine, amorolfine) and to a variety of metabolic inhibitors. The disruption of CDR2 in the C. albicans strain CAM-2 did not render cells more susceptible to these substances. When the disruption of CDR2 was performed in the background of a mutant in which CDR7 was deleted, the resulting double Acdrl Acdr2 mutant was more susceptible to these agents than the single Acdrl mutant. The absence of hypersusceptibility of the single Acdr2 mutant could be explained by the absence of CDR2 mRNA in azole-susceptible C. albicans strains. CDR2 was overexpressed, however, in clinical C. albicans isolates resistant to azole antifungal agents as described previously for CDRI, but to levels exceeding or equal to those reached b y CDRl. Interestingly, CDR2 expression was restored in Acdr7 mutants reverting spontaneously to wildtype levels of susceptibility t o azole antifungal agents. These data demonstrate that CDR2 plays an important role in mediating the resistance of C. albicans to azole antifungal agents.
INTRODUCTION
Candida albicans is an important opportunistic pathogen which can cause disseminated and mucosal infections in humans (Odds et al., 1990) . Patients with compromised immune systems, for example, patients receiving organ transplants and cancer chemotherapy or The GenBank accession number for the sequence reported in this paper is U63812.
people infected by HIV, who see their immune system gradually affected by their illness, are particularly prone to such infections. C. albicans is the major agent of oropharyngeal candidiasis in AIDS patients. Oropharyngeal candidiasis is one of the most frequent fungal infections of recent years, since it occurs in up to 90% of AIDS patients during their life span (Vanden Bossche et al., 1994a) . Among antifungal agents available to treat infections caused by C. albicans, fluconazole is by far the most commonly used compound (Powderly, 1994) . The cellular target of fluconazole and other azole derivatives in yeast is a cytochrome P450 (CYPSlAl), which is a haemoprotein involved in the 14a-demethylation of lanosterol, an important step in the biosynthesis of ergosterol (Vanden Bossche et al., 1994b) . As a consequence of the increasing number of infections caused by C. albicans, the use of this antifungal agent has been more widespread. Repeated treatments with fluconazole have led to the appearance of yeast isolates resistant to this agent in uitro (Johnson et al., 1995b; Odds, 1996; Rex et al., 1995; Vuffray et al., 1994) . In a recent study investigating the mechanisms of resistance to fluconazole in C. albicans isolates from AIDS patients with oropharyngeal candidiasis, we could demonstrate that the majority of resistant C. albicans isolates failed to accumulate the intracellular levels of fluconazole reached in susceptible isolates. This phenomenon could be correlated with an enhanced fluconazole efflux. Two multidrug efflux transporters, the ATP-binding cassette (ABC) transporter Cdrlp and the major facilitator Benp, were identified as possible mediators in this process (Sanglard et al., 1995) . The genes for these transporters, CDRI and BEN', have been isolated by Prasad et al. (1995) and Fling et al. (1991) and also in our laboratory by complementation of fluconazole hypersusceptibility of a Saccharomyces cerevisiae mutant lacking the ABC transporter PdrSplStslp (Sanglard et al., 1995) .
We expected that other factors involving efflux drug transport or other mechanisms could be responsible for the resistance of C. albicans to azole antifungal agents.
A number of other mechanisms involving alterations of the cellular target, CYP51A1, or alterations in the ergosterol biosynthetic pathway have been proposed (Marichal & Vanden Bossche, 1995) . Rather than comparing the physiology and biochemistry of azolesusceptible and azole-resistant C. albicans isolates, a more global strategy enabling the cloning of any C. albicans DNA sequences rendering the S. cereuisiae multidrug transporter mutant Apdr5 resistant to these agents was developed. The possible involvement of cloned genes in the resistance to azole antifungal agents could then be addressed in a panel of clinical isolates. Here, the results obtained using such a strategy and an extended characterization of one of the cloned genes, which was similar to CDRI and therefore named CDR2, are reported.
METHODS

Strains.
C. albicans CAF4-2 (Aura3 : : imm434/ Aura3 : : imm434) and the parent CAF2-1 (Aura3 : : imm434/ URA3) were from B. Fonzi (Fonzi & Irwin, 1993) . The S. cerevisiae strain YKKB-13 (MATa ura3-52 lys2-801amb"' ade2-101°chh'e trpl-A63 his3-A200 leu2-Al Astsl : : TRPl) has been described by Bissinger & Kuchler (1994) . The genotypes of other yeast strains are listed in Table 1 . E. coli DH5a (Hanahan, 1985) was used as a host for plasmid construction and propagation.
Media. C. albicans strains were grown on YEPD complex medium with 2% glucose, 1 '/o Bacto peptone (Difco) and 0.5 '/o yeast extract (Difco) . YEPD agar plates contained 2 ' / o agar (Difco) as a supplement. Yeast Nitrogen Base (YNB; Difco) with 2% glucose and 2% agar (Difco) was used as a selective medium after transformation of C. albicans. Agar plates containing 50 pg 5-fluoroorotic acid (5-FOA) ml-l were made for the regeneration of the ura3 genetic marker in YNB selective medium with 50 pg uridine ml-'. Drug susceptibility testing. Susceptibility of C. albicans strains to different compounds was tested qualitatively by spotting serial dilutions of yeast cultures in complex YEPD medium agar plates, which provides an easy visualization of growth differences between different yeast strains. The following drugs were solubilized in DMSO : ketoconazole and itraconazole (Janssen Pharmaceuticals), terbinafine (Sandoz Pharma), and nocodazole, brefeldin A, cerulenin and 4-nitroquinoline N-oxide (Sigma). Fluconazole (Pfizer) , amorolfine chloride (Hoffmann-La Roche) and crystal violet (Sigma) were dissolved in water. Each plate contained 15 ml agar. The drugs were diluted in the corresponding solvents to achieve the concentrations used in YEPD plates. Preliminary tests were performed to optimize drug concentrations in YEPD plates so that growth differences between the different C. albicans strains used in this study could be observed. T o perform the susceptibility tests, yeasts were grown overnight at 30 "C with constant shaking in YEPD liquid medium. The cultures were diluted to 2 x lo7 cells ml-l in 0.9 '/o NaCl. Five microlitres of this suspension and of serial dilutions of each yeast culture was spotted on each type of plate and incubated for a given time at 30 OC.
Accumulation of fluconazole in yeast.
Accumulation experiments of [3H]fluconazole (Amersham) in C. albicans CAF2-1 and in multidrug transporter mutants were performed as described previously (Sanglard et al., 1995) , except that 20 min incubation was chosen as the single sampling time. Each accumulation experiment was repeated twice.
Construction of plasmids.
For the disruption of CDR2 in C. albicans, a 2.4 kb SpeI-KpnI fragment from pDS246 was subcloned in pBluescript KS( + ) to yield pDS346. An internal 0.9 kb HindIII-PstI fragment from pDS346 was replaced by the hisG-URA3-hisG disruption cassette from pMB-7 (Fonzi & Irwin, 1993) to create pDS368. The linear 5.2 kb SpeI-KpnI fragment from pDS368 was used for disruption experiments.
Sequencing. Sequencing reactions were performed on both DNA strands by standard protocols using an AutoRead kit (Pharmacia). The reactions were analysed on an ALF automated station (Pharmacia). Sequences were obtained by primer elongation using synthesized primers (Microsynth) .
Yeast transformation. For gene disruptions, C. albicans CAF4-2 was transformed with linear fragments by an LiAc procedure developed in our laboratory. Yeast were grown to mid-exponential phase to a density of 2 x lo7 cells ml-l in 100ml YEPD complex medium with constant shaking at 250 r.p.m. Fifty millilitres of this culture was removed to a 50 ml Falcon tube and centrifuged at 5000 r.p.m. at 4 "C for 5 min. The pellet was washed twice with TE buffer (10 mM Tris/HCl, pH 7.5; 1 mM EDTA). Another washing was performed with 10ml Li/TE buffer (0.1 M LiAc in TE, pH 7.5). The final cell pellet was resuspended in 200 p1 Li/TE buffer and placed on ice. Yeast suspension (50p1) was aliquoted into Eppendorf tubes. The following reagents were added sequentially to each tube: 300 p1 of freshly prepared PEG buffer (40% PEG 4000 in Li/TE buffer), 5 pl 10 mg sheared herring sperm DNA (Clontech) ml-', then linear DNA fragments (1-2 pg) in a maximum volume of 5 p1. The tubes were mixed gently and incubated for 30 min at 30 "C. After heat shock at 42OC for 20min, the tubes were centrifuged briefly three times in a microcentrifuge at room temperature. The supernatant was removed and the cell pellet was resuspended in 200 pl TE. Aliquots of this suspension were plated in YNB selective medium and incubated for 3 4 d at 30 "C.
Plasmid rescue from 5. cerevisiae. Episomal plasmids from the parent vector YEp24 were rescued from S. cerevisiae transformants by electroporation. Yeast were grown in selective YNB medium to late-exponential phase and total DNA was extracted as outlined below. DNA suspension (1 pl) was electroporated into E. coli DHSa and ampicillin-resistant clones from each transformant were analysed by restriction enzyme analysis.
Chromosome and RNA electrophoresis, Northern blot hybridizations and quantification. Chromosomes of C. albicans were separated for gene mapping by the clamped homogeneous electric field technique (CHEF-DRII ; Bio-Rad) as described by Monod et al. (1994) .
For Northern blots, total RNA from yeast was extracted and electrophoresed following the method described in Sanglard et al. (1995) . Transfer of RNA was performed by capillarity on Genescreen Plus membranes (DuPont NEN). Membranes were pre-hybridized at 42 "C with a buffer consisting of 50 '
/ o
formamide, 1 ' / a SDS, 4 x SSC, 10% dextran sulfate and 100 yg salmon sperm DNA ml-'. [32P]DNA-labelled probes were generated by random priming (Feinberg & Vogelstein, 1984) and added to the hybridization solution overnight. Washing steps were at high stringency, identical with those recommended by the supplier (DuPont NEN). In Northern blots, the TEF3 mRNAs were analysed using a 0 7 kb EcoRI-PstI fragment from pDCl as described by Hube et al. (1994) . Stripping of probes in sequential hybridizations was achieved by boiling the membranes for 10 min in 0.1 ' / o SDS in TE buffer. Details about other probes are described in the legend of the corresponding figures.
Quantifications of Northern blots were performed by exposure of the hybridized membranes in an Instant Imager (Packard Instrument). Signals were integrated by the software supplied by the manufacturer and normalized to the corresponding values of the TEF3 internal standard. PCR. PCR buffers and AmpliTaq polymerase were from Perkin Elmer (Roche Molecular Systems). The buffer composition was 10 mM Tris/HCl (pH 8*3), 50 mM KCl and 1.5 mM MgCl, containing 0-2 mM dNTPs and 2.5 U polymerase per reaction. Briefly, the PCR was carried out in a Thermal Cycler 480 (Perkin Elmer) with a first cycle of denaturation for 4 min at 94 OC followed by 30 cycles of annealing at 54 "C for 2 min, elongation at 72 "C for 2 min and denaturation at 94 "C for 30 s. PCR was completed by a final elongation step at 72 "C for 10 min. Primers for PCR are described in Fig. 5 and were designed on the basis of the C. albicans CDR2 and Salmonella typhirnuriurn hisG nucleotide sequences in the GenBank database.
Yeast DNA templates for PCR were prepared from overnight cultures on complex medium. A 1 ml portion of these cultures was centrifuged in an Eppendorf tube and DNA was extracted by adding 0.3 g glass beads, 200 yl of a breaking buffer (2% Triton X-100, 1 ' / o SDS, 10 mM Tris/HCl, pH 8.0, 1 mM EDTA, 100 mM NaC1) and 200 p1 phenol/chloroform/ isoamyl alcohol (24 : 24 : 1, by vol.). After 1 min vortexing, the tubes were centrifuged at maximum speed for 10 min in the microcentrifuge and the supernatant was re-extracted with chloroform/isoamyl alcohol (24 : 1, V/V) . Nucleic acids were then precipitated with ethanol and resuspended in 50 pl TE. Of this suspension, 1 p1 was used for PCR.
RESULTS
Cloning of C. albicans genes conferring resistance to azole antifungal agents W e reported recently than a n S. cerevisiae mutant YKKB-13 lacking the ABC transporter PdrSp was hypersusceptible to azole antifungal agents (Sanglard et al., 1995) . This phenotype seemed to be adequate for complementing hypersusceptibility with any C. albicans DNA segment carrying genes of resistance to azole antifungal agents. These genes are thus likely to encode multidrug efflux transporters ; however, they may belong to totally unrelated genes. A C. albicans genomic library from strain SC5314 was therefore constructed in the episomal vector YEp24 (Sanglard et al., 1995 ) and the resulting library was transformed in the S. cerevisiae strain YKKB-13. A total of 40000Ura' clones was obtained a n d spotted in selective YNB plates containing in a first screening 10 pg fluconazole ml-'. Thirty-two azole-resistant clones emerged and their plasmids were rescued in E. cola' DHSa by electroporation. Plasmids with unique and not overlapping restriction sites were selected and re-transformed in YKKB-13. After this selection, five different plasmids, each potentially carrying a unique resistance gene, were isolated. The same screening procedure was used with 0.2 pg ketoconazole ml-l in selective YNB medium. This procedure yielded plasmids, some of them with the same profiles as those obtained by fluconazole selection. However, one additional unique plasmid with a resistance gene was isolated, bringing the total number of resistance genes to six. Table 2 summarizes the pattern of resistance produced by each of these plasmids in YKKB-13, not only to azole antifungal agents but also to other antifungals and different metabolic inhibitors. All plasmids conferred resistance to fluconazole but to different degrees; for example, the presence of pDS243, pDS239 and pDS255 in YKKB-13 allowed cells to grow at all dilutions tested in a medium with 5 pg fluconazole ml-l whereas cells containing pDS246, pDS2.57 and pDS270 exhibited visible growth only up to dilutions of and 10-l. While pDS239, pDS25.5 and pDS2.57 yielded specific resistance to fluconazole, only pDS243, pDS246 and pDS270 could confer cross-resistance to all three azole derivatives used in this study, but to different extents. pDS243 and pDS239, whose restriction maps are shown in Fig. 1 , have been reported in a previous study and contained the CDRl and BENr genes (Sanglard et al., 1995) . CDRZ had previously been cloned by Prasad et al. (1995) by complementation of cycloheximide hypersusceptibility of an S. cerevisiae Apdr.5 mutant, while BEN' was cloned by Fling et al. (1991) in experiments where resistance to benomyl was conferred to another S. cereuisiae strain. The pattern of resistance of yeast transformed by the CDRl -containing plasmid pDS243 covers a wide range of substances (Table 2 ). This feature is typical of multidrug transporters of the ABC family, but among these substances are amorolfine and terbinafine, which are antifungals of medical relevance (Vanden Bossche et al., 1994b) , sulfomethuron methyl, rhodamine 6G, cerulenin and brefeldin A. These compounds have not yet been reported as substrates for this transporter. pDS239, which contained BEN', besides conferring resistance to already reported substances such as cycloheximide, benomyl and 4-nitroquinoline N-oxide (Goldway et al., 1995) , could also accept as new substrates terbinafine, sulfomethuron methyl, 1,lO-phenanthroline, cerulenin and brefeldin A (Table 2) . Among these new substrates, terbinafine, sulfomethuron methyl, cerulenin and brefeldin A can be used as substrates by both multidrug transporter classes. Specific substrates for Benp are Table 2 ). Only maps o f -
benomyl, 1,lO-phenanthroline and 4-nitroquinoline Noxide.
pDS246 conferred resistance to all azole derivatives, as mentioned above, and to a very similar variety of other metabolic inhibitors as CDRI, but with less potency than this gene. However, pDS246 seemed to confer a specific resistance to crystal violet (Table 2 ). Restriction mapping of pDS246 was performed ( Fig. 1 ) and sequence analysis showed that an ORF encoding 1499 aa was present in the insert of this plasmid (see also Fig. 2 ). This ORF had a high identity (84 YO) to that in CDRI (Prasad et al., 1995) and therefore it was named CDR2.
The genes carried by the other plasmids listed in Table  2 , namely pDS255, pDS257 and pDS270, contained, according to the data available from total or partial nucleotide sequences, unidentified C. albicans genes when compared with the current GenBank database (this will be reported elsewhere). In this study, we focused only on CDR2, since it is closely related to CDRI and is possibly involved in resistance to azole antifungal agents in clinical C. albicans isolates.
Sequence analysis of CDR2
A 5800 bp NlaIV-EcoRI fragment from pDS246, which was expected from partial nucleotide sequence analysis to contain the entire CDRZ gene, was subcloned with available restriction sites and its nucleotide sequence was determined. An uninterrupted ORF of 4500 bp starting from the most upstream ATG codon was observed in this fragment. The 5'-flanking region starting from this ATG codon displayed conserved features of typical yeast promoters: an adenosine at position -3 and a TATA box at position -111 (Chen & Struhl, 1988) could be clearly distinguished. Interestingly, in the 3'-flanking region of the nucleotide sequence in Fig. 2 The CDR2 ORF encodes a protein of 168 kDa and displays a structure and domain organization typical of membrane proteins of the ABC superfamily. It is 84% identical and 92 O/O similar to Cdrlp ; however, alignment of the two amino acid sequences shows that the N-and C-terminal portions of both proteins were more divergent (Fig. 3) . As in the case of Cdrlp, Cdr2p is composed of two homologous halves, each comprising a C-hydrophilic and an N-hydrophobic domain. The hydropathy plot of Cdr2p identified six putative transmembrane domains for each of the hydrophobic domains (see Fig. 2 ). Each hydrophilic domain included ATP-binding motifs found in ATP-binding cassette domains. In the N-terminal ABC domain, the Walker A (GRPGAGCST) and B (IQCVD) motifs and the ABC signature (VSGGERKRVSIA) are identical in both proteins. In the C-terminal ABC domain, both the Walker A (GASGAGKT) and Walker B (LLFLD) regions are present in both proteins, but no typical ABC signature is present.
The high similarity between the amino acid sequences of Cdrlp and Cdr2p does not, however, extend to the regions flanking the ORF of both genes. The 5'-flanking and promoter regions of both genes are especially divergent and thus suggest that these genes may differ in their regulation.
Expression of CDR2 in clinical C. albicans isolates
To address the possible expression of CDR2 in C. albicans, two pairs of C. albicans clinical isolates were selected, each of which contained closely related isolates susceptible and resistant to azole antifungal agents. These strains were isolated from two different AIDS patients with oropharyngeal candidiasis and were analysed in a previous study in which the resistant isolate of each pair was reported to overexpress CDRI (Sanglard et al., 1995) . Total RNA from the isolates was extracted and subjected to Northern blot analysis with probes specific for CDRZ and CDR2. These probes were of identical length and spanned the same 5'-flanking regions of both genes, where the degree of homology between the two genes is very low. Thus, no crosshybridization between the two probes could be expected. As presented in Fig. 4 , CDRl was expressed constitutively but at low levels in strains still susceptible to azole antifungal agents and, as expected, increased expression was observed when the isolates of each pair became resistant to the same agents. Quantifications with the Instant Imager (see Methods) revealed that the expression of CDRZ was increased in C34 over C26 and in CS6 over C43 by 2.7-fold and 4.5-fold7 respectively, thus confirming results obtained in a previous study with the same strains (Sanglard et al., 1995). Conversely CDR2 was not expressed in the same susceptible isolates, and most surprisingly, this gene was overexpressed when the isolates became resistant to azole antifungal agents. The relative CDR2 mRNA levels exceeded those of CDRZ by a factor of 6 in isolate C26 and only slightly those of C D R I , by a factor of 1.3, in isolate C56. 
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I I I I I I I :: I I I I I I I I : I I I I I IT1 I I I I I I I I :. 11::. .;:I. I 11: I I I I I I I I I I C34 and C26, and C43 and C56 are azole-susceptible and azoleresistant pairs from two distinct patients. These strains have been characterized and have been tested for their susceptibility to fluconazole, itraconazole and ketoconazole as described previously (Sanglard et a/., 1995) . The Northern blot was probed sequentially with CDR7 and CDR2 probes and finally a T€F3 probe as an internal standard for normalization of the loaded quantities. Specific CDRI and CDR2 probes were generated by PCR with primers spanning the nucleotide regions -109 to t-280 and -112 to +274 with respect to the first ATG initiation codon of the published sequences. The identity between the two probes a t the level of the nucleotide sequence is below 50%. The figure shows the signal intensities obtained with the CDRI and CDR2 probes after 9 and 18h exposure of membranes on an RX Fuji X-ray film a t -70°C. Signal intensities with the TEF3 probes were obtained after 3 h exposure on the same X-ray film.
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Disruption of the CDR2 gene
T o investigate the effect of Cdr2p in C. albicans, the gene encoding this protein was deleted by targeted gene disruption by the method described by Fonzi & Irwin (1993) . CAF4-2, and also a strain named DSY449 (Table  1) in which both alleles of CDRI were deleted (Sanglard et al., 1996) , were utilized as recipients for transformation with a linear fragment in which a substantial region of CDR2 was deleted and replaced by the his G-URA3-h is G URA3 -blas ter disruption cassette (see Fig. 5 ) . An LiAc transformation protocol was utilized here and yielded approximately 100 Ura+ transformants (pg linear fragment)-'. A PCR method was applied in this study to screen Ura+ transformants for the correct localization of the disruption of the first CDR2 allele. This approach consisted of using a pair of primers where one was specific for the hisG gene and the other would anchor a site flanking the region of homologous recombination between the genomic locus and the linear DNA fragment (see Fig. 5 ) . Ten Ura' transformants for each disruption in CAF4-2 and DSY449 were screened and they all showed the correct genotype. PCR analysis of only one of these clones for each disruption strategy marked by a bar. Colons and periods indicate high and low conservative replacements between the two proteins. Walker A and B domains and the ABC signature are underlined. The alignment was generated by the method of Needleman & Wunsch (1970) implemented in the program GAP of the GCG package of the University of Wisconsin. CDRZ-specif ic), B (5'-GGCGCGACfTCGACAGAAC-3', hisG-specific) and C (5'-GTGCACAGTGCACACATTAACC-3', CDRZ-specific) used in PCR for the monitoring of disruption (Fig. 6 ) is indicated. The linear fragment containing the gene deletion construct as represented in panel I and which was used for disruption experiments was the 5.2 kb Spel-Kpnl fragment from pDS368.
(DSY649 and DSY650) is shown in Fig. 6 . As expected, PCR performed with primers A (specific for the CDR2 gene) and B (specific for the hisG gene) with genomic DNA of these strains yielded a major PCR product of 1-6 kb. One positive transformant of each first allele disruption was further treated with 5-FOA to regenerate the ura3 genetic marker. The regeneration of the ura3 marker by recombination between hisG repeats rather than by mitotic recombination between the wild-type allele and the first disrupted alleles was verified on 5-FOA-resistant strains by PCR analysis. In each case, four 5-FOA-resistant clones were analysed and all had the desired genotype. Only PCR analysis of one representative of each marker regeneration (DSY651 and DSY652) is shown on Fig. 6 . PCR products from DSY651 and DSY652 using primers A and C (both specific for CDR2) were obtained with sizes of 2.1 and 2.4 kb, corresponding to the sizes expected from the wild-type allele and the Acdr2 : : hisG disrupted allele, respectively.
The linear fragment containing the CDR2 deletion construct was then re-used for the disruption of the second CDR2 allele in both cases. PCR analysis was used again to select Ura+ transformants where both alleles were disrupted. On this selection basis, the Ura+ Acdr2 and Acdrl Acdr2 homozygous deletion mutants DSY653 and DSY654 could be successfully isolated. Only 2 out of 10 Ura+ transformants in the case of the CDR2 disruption in the CAF4-2 genetic background and only one 1 out of 33 Ura' transformants in the case of the CDR2 disruption in the Acdrl deletion mutant background had this correct genotype. The other transformants in both cases were still heterozygous for the gene deletions, since homologous recombination of the disruption cassette with the first disrupted Acdr2: :hisG alleles rather than with the wild-type CDR2 alleles had occurred in both cases. Verification of the gene deletions in DSY653 and DSY654 was performed with Southern blot analysis using hisG as a probe. No signals other than those expected by the gene replacement of the wild-type alleles by the disrupted alleles were observed in this analysis, thus confirming the results obtained by PCR analysis with respect to the identification of the constructed mutants (data not shown). The Acdr2 homozygote deletion mutants created were then used in drug susceptibility assays.
Drug susceptibility assays with Acdr2 and Acdrl Acdr2 mutants
Recently, the usefulness of multidrug transporter mutants for addressing the function of multidrug transporters and for assigning unrelated compounds as possible substrates of these proteins in C. albicans was reported (Sanglard et al., 1996) . Since many of these compounds inhibit the growth of C . albicans, it is therefore possible to assign them to putative substrates of multidrug transporters by observing growth variations between different yeast types on agar plates containing the different inhibitors. A reduced growth of a given mutant in the presence of a defined inhibitor can be the consequence of an increased accumulation of the substance due to the absence of its specific efflux transporter. The previously constructed Acdrl mutant DSY448 was shown in fact to be hypersusceptible, not only to azole antifungal agents, but also to other metabolic inhibitors (Sanglard et al., 1996) . Fig. 7 presents these features and one can observe that every listed compound affected, but to different extents, the growth of DSY448 compared to the wild-type CAF2-1. When the Acdr2 deletion mutant DSY653 was exposed to the same array of compounds listed in Fig. 7 , however, the growth of this mutant was surprisingly not affected.
Only when the CDR2 gene deletion is constructed in a Acdrl background can a more severe growth inhibition be observed compared to the single Acdrl deletion mutant for almost every compound tested. Exceptions were found in plates containing nocodazole and crystal violet, where no difference in growth was found between the single Acdrl and the double Acdrl Acdr2 mutants. Table 1. of the Acdrl Acdr2 mutant DSY654 compared to the Acdrl mutant DSY448 (Fig. 7) .
The reason for the lack of hypersusceptibility of the Acdr2 deletion mutant was clearer when the mRNA levels of this gene were measured in the parent strain CAF2-1 or in other azole-susceptible strains. In fact, no CDR2 mRNA was detected in these cells (Figs 4 and 8) , even in the Acdrl mutant DSY447, which is the parent of the Acdrl Acdr2 mutant DSY654 (data not shown). Taking these observations into account, it is expected that, when CDR2 is deleted in these strains, no phenotypic effect with respect to drug susceptibility can be observed.
CDR2 is expressed in multidrug transporter mutants reverting spontaneously to normal f luconazole susceptibility
We observed that, after a prolonged incubation of the Acdrl and Acdrl Aben deletion mutants DSY448 and DSY468 (which are described elsewhere; Sanglard et al., 1996) on plates containing fluconazole, some colonies spontaneously grew over a layer of spotted cells. The frequency at which these colonies appeared fluctuated between 1 x low4 and 3 x Some of these cells were grown in drug-free YEPD medium and spotted again on plates containing fluconazole. To our surprise, five randomly chosen isolates, which were named Rl-R5, were more resistant to fluconazole than their hypersusceptible parents. The same revertants regained resistance to ketoconazole and itraconazole (Table 3 ) . This effect was not due to the expression of BEN', since Acdrl Aben mutants generated spontaneous revertants at the same frequency, and since overexpression of BENr can only render cells resistant to fluconazole. A Northern blot of RNA extracted from the revertant strains R1-R5 showed that CDRl mRNA was, as expected, effectively absent from these cells, but that the CDR2 gene was expressed (Fig. 8) . The level of this expression was low but significant in these cells when compared to the absence of expression in CAF2-1 or DSY447. Therefore it appears that the expression of CDR2 seems to be responsible for the reversion of Rl-R5 to wild-type levels of susceptibility not only to fluconazole but also to itraconazole and ketoconazole. This result is not entirely unexpected given that CDR2 is clearly overexpressed in resistant strains (Fig. 4) and that it participates with CDRZ in the resistance of C. albicans to azole antifungal agents. 
DISCUSSION
We report here the cloning of different C. albicans genes which conferred resistance to different antifungal agents, including azole derivatives, and to other unrelated metabolic inhibitors. Not only were the CDRZ and the BEN' genes re-isolated by a screening procedure consisting of complementing the fluconazole hypersusceptibility of an S. cerevisiae Apdr5 mutant, but other additional genes were cloned using the same compound and with ketoconazole as a selective agent. Among these additional genes, a new ABC transporter gene closely related to CDRI was characterized and therefore named CDR2. Prasad et al. (1995) utilized a similar strategy to clone multidrug resistance genes with a similar S. cereuisiae mutant but using cycloheximide as a selective agent in the screening procedure and two C. albicans genomic libraries based on single copy and multicopy vectors. Seventy-four different clones were isolated by these authors, which is much higher than in our case, although this result did not take into account the number of clones with overlapping restriction maps. The high number of clones obtained by Prasad et al. (1995) could have been due to the nature of the selective agent, which probably allows the cloning of genes whose action on drug resistance is much less specific than azole antifungal agents. Our preliminary data on the identity of the additional genes cloned in this study and which are different from CDRZ, BEN' and CDR2 suggest that pDS255 and pDS257 contained genes similar to BENr and to the S. cerevisiae transcription factor YAPZ, respectively (D. Sanglard, unpublished).
The method of cloning resistance genes by functional complementation is of potential interest for obtaining similar genes from other pathogenic organisms. Candida glabrata and Candida krusei, for example, are organisms becoming more frequent in fungal infections and they exhibit lower intrinsic susceptibility to fluconazole than measured in C. albicans (Essayag et at., 1996; Johnson et al., 1995a; Odds et al., 1996) . Some reports document resistance to azole antifungal agents in C. glabrata and C. krusei after prolonged exposure to these agents (Berrouane et al., 1996 ; Chavanet et al., 1994; Hitchcock et al., 1993; Parkinson et al., 1995; Vanden Bossche et al., 1992) , so understanding mechanisms of resistance in these isolates is becoming more important. Table 2 gives an overview of the pattern of resistance of the cloned genes to different classes of antifungal agents and metabolic inhibitors. Besides the resistance conferred to three important azole derivatives by overexpression of CDRI and CDR2 in S. cerevisiae, it is noteworthy to mention the cross-resistance to other classes of antifungal agents such as terbinafine and amorolfine, which are used, as in the case of azole derivatives, in the treatment of different fungal infections. It is of interest that the expression of BEN' in the same host could make cells resistant to terbinafine and to a lesser extent to amorolfine. These features have an important impact for the treatment of fungal infections, since it is possible that resistance to azole antifungals mediated by the overexpression of multidrug transporters can extend to the other still-available antifungal agents. The Cdr2p protein shares high similarity with Cdrlp, which in turn displays a high degree of similarity with the S. cerevisiae PdrSp (Balzi et al., 1994; Bissinger & Kuchler, 1994) . The functional complementation of CDRI and CDR2 in an S. cerevisiae multidrug transporter mutant Apdr5 allows the two gene products to be distinguished from each other by the differences in pattern of resistance to various substances. The Cdr2p protein seems to have a lower potency than Cdrlp in the degree of resistance conferred to S. cerevisiae, but gives a specific resistance to crystal violet. Interestingly, the S. cerevisiae gene SGEI, which encodes a protein belonging to the class of major facilitators, also confers specific resistance to crystal violet when overexpressed (Ehrenhofer et al., 1994) . Whether or not the differences in resistance patterns between Cdrlp and Cdr2p are due to amino acid substitutions between the two proteins remains to be determined; for example, the features observed for the two proteins may still not be valid in the context of expression in C. albicans, since the coding region of CDR2, as opposed to C D R I , contains three CUG codons (see Fig. 2 ) which are known to be translated to serine in this host and not to leucine as is the case in S. cerevisiae (Santos & Tuite, 1995) . The most interesting feature of CDR2 at the moment is its regulation in C. albicans. As judged by the absence of CDR2 mRNA signals after autoradiography of the Northern blot shown in Fig. 4 , CDR2 was not expressed at levels detectable by this method in clinical C. albicans strains susceptible to azole antifungal agents, but was overexpressed in isolates which became resistant to these agents. In a previous study (Sanglard et al., 1995) , we showed that CDRI was overexpressed in these strains. The probe for CDRI generated at that time did not discriminate between CDRI and CDR2 and thus the signal measured comprised the sum of the CDRI-and CDR2-specific signals. The elevated expression of CDRI and CDR2 could be due to the action of the same or distinct transacting factors which remain to be characterized. The available sequence information on the promoters of both genes reveals no identical nucleotide regions and thus a common regulatory region cannot be assumed.
CDR2 expression can also be observed in multidrug transporter mutants when they revert spontaneously to wild-type levels of susceptibility to azole antifungal agents ( Fig. 8 ; Table 3 ). The expression of CDR2 in these revertants can be considered a plausible explanation for this effect. Available data suggest that these revertants are even slightly more resistant than the wildtype parent CAF2-1 to azole derivatives ( Table 3) .
Although we cannot exclude that other resistance factors may operate in these revertants, the restored CDR2 expression stresses the importance of this multidrug efflux transporter in the understanding of the mechanisms of resistance to azole antifungal agents in C. albicans.
The disruption of the CDR2 gene in C. albicans CAF4-2 did not result in hypersusceptibility to the substances tested in this study. Although CDRI (which is present in this strain) may compensate for the deletion of CDR2, it could also be argued that a residual Cdr2p activity might exist in the created homozygous Acdr2 deletion mutant. It was not possible to measure the absence of CDR2 mRNA in the created mutant, since the wild-type parent already did not exhibit detectable CDR2 expression. However, the data available on the identity of the homozygous Acdr2 deletion mutant allow us to ascertain a correct genotype. We believe that the lack of hypersusceptibility of the Acdr2 mutant reflects the absence of CDR2 expression in CAF4-2.
Several lines of evidence now suggest that multidrug transporter genes of the class of ABC transporters may be members of a larger multigene family in C. albicans. Besides the cloning of CDRI and CDR2, preliminary data from a screening of a C. albicans genomic library with a conserved multidrug ABC transporter gene probe resulted in the isolation of at least two distinct genes with similarity to the two genes mentioned above isolated by functional screening. It will be interesting to resolve the complexity of this gene family in the future and to determine if only specific members of this multigene family are involved in resistance to azole antifungal agents in C. albicans. 
